Catalent

CTLT · NYSE

Price unavailable right now.

No price history for this range.

Latest news

NewsAug 25, 1:59 PM ETVandana Singh
FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles
Press releaseFeb 20, 9:00 AM ETBusiness Wire
Catalent Announces New Board Appointments
Press releaseDec 18, 5:46 PM ETPRNewswire
Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
Press releaseDec 18, 8:57 AM ETBusiness Wire
Novo Holdings Completes Acquisition of Catalent
NewsDec 16, 8:32 AM ETVandana Singh
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Press releaseDec 14, 12:06 AM ETBusiness Wire
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction
Press releaseDec 10, 7:00 AM ETBusiness Wire
QuidelOrtho Announces Appointment of Two Independent Directors to its Board
Press releaseDec 6, 1:08 PM ETBusiness Wire
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction
Press releaseNov 5, 7:00 AM ETBusiness Wire
Catalent, Inc. Reports First Quarter Fiscal 2025 Results
NewsOct 23, 7:05 PM ETVandana Singh
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
NewsOct 21, 7:03 AM ET
Catalent's CEO Confirms Leadership Continuity As Novo Holdings Acquisition Nears
Press releaseOct 21, 7:00 AM ETBusiness Wire
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
NewsOct 18, 2:39 PM ETVandana Singh
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Press releaseOct 14, 6:00 AM ETBusiness Wire
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
NewsOct 10, 9:32 AM ET
'Warren urges FTC to probe deal that would give Novo Nordisk control of some Catalent plants; At issue is whether the deal would give Novo an unfair advantage in the market for obesity, diabetes drugs' - STAT News
Press releaseAug 29, 7:30 AM ETBusiness Wire
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
Press releaseJul 16, 2:00 AM ETBusiness Wire
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles

Catalent Announces New Board Appointments

Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

Novo Holdings Completes Acquisition of Catalent

Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent

Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction

QuidelOrtho Announces Appointment of Two Independent Directors to its Board

Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction

Catalent, Inc. Reports First Quarter Fiscal 2025 Results

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition

Catalent's CEO Confirms Leadership Continuity As Novo Holdings Acquisition Nears

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings

After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent

Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility

'Warren urges FTC to probe deal that would give Novo Nordisk control of some Catalent plants; At issue is whether the deal would give Novo an unfair advantage in the market for obesity, diabetes drugs' - STAT News

Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results

Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany